Luis V. Colom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis V. Colom has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Antonio García-Hernández
Department of Biological Sciences at the University of Texas at Brownsville/Texas Southmost College, 80 Fort Brown, Brownsville, TX 78520, USA
3 shared publications- George Perry
University of Texas at San Antonio
3 shared publications Sofia Hernandez
3 shared publicationsAhmed Touhami
Physics and Astronomy Department, The University of Texas at Brownsville, Brownsville, TX, USA
2 shared publicationsEmilio R. Garrido-Sanabria
Department of Biological Sciences, The Center for Biomedical Studies, The University of Texas at Brownsville, 80 Fort Brown, Brownsville, TX 78520, USA
2 shared publicationsM.T. Castaneda
Center for Biomedical Research, University of Texas at Brownsville, 80 Fort Brown, Brownsville, TX 78520, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4, 119
Biological Basis for Cerebral Dysfunction in Schizophrenia in Contrast with Alzheimer’s Disease
Schizophrenia and Alzheimer’s disease are two disorders that, while conceptualized as pathophysiologically and clinically distinct, cause substantial cognitive and behavioral impairment worldwide, and target apparently similar — or nearby — circuitry in regions such as the temporal and frontal lobes. We review the salient differences and similarities from selected historical, nosological and putative mechanistic viewpoints, as a means to help both clinicians and researchers gain a better insight into these intriguing disorders, for which over a century of research and decades of translational development was needed to begin yielding treatments that are objectively effective, but still very far from entirely satisfactory. Ongoing comparison and “cross-pollination” among these approaches to disorders that produce similar deficits is likely to continue improving both our insight into the mechanisms at play, and the development of biotechnological approaches to tackle both conditions — and related disorders — more rapidly and efficaciously.
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4, 119
Open AccessBiological Basis for Cerebral Dysfunction in Schizophrenia in Contrast with Alzheimer’s Disease
Schizophrenia and Alzheimer’s disease are two disorders that, while conceptualized as pathophysiologically and clinically distinct, cause substantial cognitive and behavioral impairment worldwide, and target apparently similar — or nearby — circuitry in regions such as the temporal and frontal lobes. We review the salient differences and similarities from selected historical, nosological and putative mechanistic viewpoints, as a means to help both clinicians and researchers gain a better insight into these intriguing disorders, for which over a century of research and decades of translational development was needed to begin yielding treatments that are objectively effective, but still very far from entirely satisfactory. Ongoing comparison and “cross-pollination” among these approaches to disorders that produce similar deficits is likely to continue improving both our insight into the mechanisms at play, and the development of biotechnological approaches to tackle both conditions — and related disorders — more rapidly and efficaciously.
- 7 March 2013
- Published by Elsevier in Neurobiology of Aging
- Vol. 34 (8) , 2071-2076
Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system
- 7 March 2013
- Published by Elsevier in Neurobiology of Aging
- Vol. 34 (8) , 2071-2076
Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system
- 28 February 2013
- Published by Elsevier in Neuroscience Letters
- Vol. 541, 54-57
Memantine protects cholinergic and glutamatergic septal neurons from Aβ1–40-induced toxicity
- 28 February 2013
- Published by Elsevier in Neuroscience Letters
- Vol. 541, 54-57
Memantine protects cholinergic and glutamatergic septal neurons from Aβ1–40-induced toxicity
- 1 January 2013
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 10 (1) , 108-116
Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer’s Disease
Despite over one hundred years of intense effort studying Alzheimer’s disease (AD), we still do not understand its cause(s) and this adversely affects our ability to develop strongly effective treatments and means to prevent it. This is because our research efforts are not aligned to decipher this age-related disorder that, well after its discovery, has become a major cause of death throughout the world. We are therefore recommending a process to analyze some of the principal factors that hinder our progress in this field of research. Recognizing these barriers — and acting on such a recognition by seeking to resolve them experimentally and garnering societal support to do so — will constitute critical steps towards establishing strategies that will lead to a sorely needed paradigm shift in AD research, and ultimately to the prevention and the effective treatment of this devastating condition. This will probably also spur progress in many related neuropsychiatric disorders, and in that sense act as a seminal endeavor with far-reaching consequences. In order to accomplish this complex task, the biomedical community must acknowledge and come to a consensus about the factors that limit our progress, and then work together to generate new algorithms to tackle these fundamental issues rationally, effectively and deliberately.
- 1 January 2013
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 10 (1) , 108-116
Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer’s Disease
Despite over one hundred years of intense effort studying Alzheimer’s disease (AD), we still do not understand its cause(s) and this adversely affects our ability to develop strongly effective treatments and means to prevent it. This is because our research efforts are not aligned to decipher this age-related disorder that, well after its discovery, has become a major cause of death throughout the world. We are therefore recommending a process to analyze some of the principal factors that hinder our progress in this field of research. Recognizing these barriers — and acting on such a recognition by seeking to resolve them experimentally and garnering societal support to do so — will constitute critical steps towards establishing strategies that will lead to a sorely needed paradigm shift in AD research, and ultimately to the prevention and the effective treatment of this devastating condition. This will probably also spur progress in many related neuropsychiatric disorders, and in that sense act as a seminal endeavor with far-reaching consequences. In order to accomplish this complex task, the biomedical community must acknowledge and come to a consensus about the factors that limit our progress, and then work together to generate new algorithms to tackle these fundamental issues rationally, effectively and deliberately.
- 1 December 2011
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 8 (8) , 832-840
Intrahippocampal amyloid-? (1-40) injections injure medial septal neurons in rats.
Abstract: Alzheimers disease (AD) is a devastating disorder that leads to memory loss and dementia. Neurodegeneration of cholinergic neurons in the septum and other basal forebrain areas is evident in early stages of AD. Glutamatergic neurons are also affected early in AD. In these stages, amyloid-β-peptide (Aβ) plaques are present in the hippocampus and other cortices but not in the basal forebrain, which includes the septum. We postulate that early deposition of hippocampal Aβ damages the axon terminals of cholinergic and glutamatergic septo-hippocampal neurons, leading to their degeneration. To determine the mechanisms underlying septal degeneration, fibrillar Aβ1-40 was injected into the Cornu Ammonis (CA1) hippocampal region of rats. Controls were injected with reverse peptide Aβ40-1. A 16% reduction in NeuN+ cells was observed around the injection sites when compared to controls (p
- 1 December 2011
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 8 (8) , 832-840
Intrahippocampal amyloid-? (1-40) injections injure medial septal neurons in rats.
Abstract: Alzheimers disease (AD) is a devastating disorder that leads to memory loss and dementia. Neurodegeneration of cholinergic neurons in the septum and other basal forebrain areas is evident in early stages of AD. Glutamatergic neurons are also affected early in AD. In these stages, amyloid-β-peptide (Aβ) plaques are present in the hippocampus and other cortices but not in the basal forebrain, which includes the septum. We postulate that early deposition of hippocampal Aβ damages the axon terminals of cholinergic and glutamatergic septo-hippocampal neurons, leading to their degeneration. To determine the mechanisms underlying septal degeneration, fibrillar Aβ1-40 was injected into the Cornu Ammonis (CA1) hippocampal region of rats. Controls were injected with reverse peptide Aβ40-1. A 16% reduction in NeuN+ cells was observed around the injection sites when compared to controls (p
- 31 August 2011
- Published by Elsevier in Neuroscience Research
- Vol. 70 (4) , 361-369
Differential expression of voltage-gated K+ currents in medial septum/diagonal band complex neurons exhibiting distinct firing phenotypes
- 31 August 2011
- Published by Elsevier in Neuroscience Research
- Vol. 70 (4) , 361-369
Differential expression of voltage-gated K+ currents in medial septum/diagonal band complex neurons exhibiting distinct firing phenotypes
- Open Access
- 20 July 2010
- Published by Springer Nature in BMC Neuroscience
- Vol. 11 (S1) , P125
Selective lesions of medial septal GABAergic neurons disrupt Hippocampal Theta Rhythm Amplitude
- 20 July 2010
- Published by Springer Nature in BMC Neuroscience
- Vol. 11 (S1) , P125
Open AccessSelective lesions of medial septal GABAergic neurons disrupt Hippocampal Theta Rhythm Amplitude
- 31 March 2010
- Published by Elsevier in Experimental Neurology
- Vol. 222 (1) , 86-92
Septo-hippocampal networks in chronic epilepsy
- 31 March 2010
- Published by Elsevier in Experimental Neurology
- Vol. 222 (1) , 86-92
Septo-hippocampal networks in chronic epilepsy
- 1 January 2010
- Published by Elsevier in Neurobiology of Aging
- Vol. 31 (1) , 46-57
Medial septal β-amyloid 1-40 injections alter septo-hippocampal anatomy and function
- 1 January 2010
- Published by Elsevier in Neurobiology of Aging
- Vol. 31 (1) , 46-57
Medial septal β-amyloid 1-40 injections alter septo-hippocampal anatomy and function
- 1 May 2007
- Published by Elsevier in Neuroscience
- Vol. 146 (3) , 931-945
Electrophysiological and morphological heterogeneity of slow firing neurons in medial septal/diagonal band complex as revealed by cluster analysis
- 1 May 2007
- Published by Elsevier in Neuroscience
- Vol. 146 (3) , 931-945
Electrophysiological and morphological heterogeneity of slow firing neurons in medial septal/diagonal band complex as revealed by cluster analysis